Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9776339 | 0.79 | ALDH1A1 (0.41) | CA12CA1CA2CA7CA9 | |
| SCHEMBL64953 | 0.78 | ALDH1A1 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2251771 | 0.73 | CYP1A2 (0.59) | CYP1A2CYP1A1CYP1B1CYP2A6ALDH1A1 | |
| SCHEMBL8558574 | 0.72 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11723042 | 0.72 | CYP2A6 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5144913 | 0.70 | CYP2A6 (0.50) | CYP1A2CYP2A6CYP3A4MEN1KMT2A | |
| SCHEMBL11049075 | 0.70 | CYP1A2 (0.46) | CYP1A2CYP1A1CYP1B1CYP2A6MEN1 | |
| SCHEMBL21830263 | 0.69 | CYP1A2 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9510748 | 0.69 | CYP2A6 (0.48) | CYP1A2CYP2A6CYP3A4MEN1KMT2A | |
| SCHEMBL8933817 | 0.69 | CYP2A6 (0.44) | CYP1A2CYP2A6ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| US-6844173-B2 | Strain of Streptomyces griseus | SANKYO COMPANY, LIMITED (JP) | 2005-01-18 | — | — | US | disclosed |
| CN-1181087-C | Novel antibacterial compounds | ������������ʽ���� | 2004-12-22 | — | — | CN | disclosed |
| CN-1176936-C | Carbamycin derivatives and pharmaceutical compositions containing the same | ������������ʽ���� | 2004-11-24 | — | — | CN | disclosed |
| CN-1525968-A | composition for preventing or treating liver disease | 三共株式会社 | 2004-09-01 | — | — | CN | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1319406-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| CN-1091432-A | Can suppress the active peptide of hiv protease, its preparation with and medical use | SANKYO CO (JP) | 1994-08-31 | — | — | CN | disclosed |
| CN-1091128-A | Piperidine derivative | SANKYO CO (JP) | 1994-08-24 | — | — | CN | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0283310-B1 | N-BENZHYDRYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR USE | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
| CN-1064683-A | New beta-amino-alpha-hydroxycarboxylic acids and uses thereof | SANKYO CO (JP) | 1992-09-23 | — | — | CN | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| US-5028610-A | Calcium Channel Blockers | SANKYO COMPANY LIMITED (JP) | 1991-07-02 | — | — | US | disclosed |
| EP-0283310-A1 | N-Benzhydryl-substituted heterocyclic derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | CA12 4002/4885CA1 4733/4885CA2 4691/4885 |
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | CA12 3974/4885CA1 2594/4885CA2 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.